1. Home
  2. QLGN vs VRPX Comparison

QLGN vs VRPX Comparison

Compare QLGN & VRPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • VRPX
  • Stock Information
  • Founded
  • QLGN 1996
  • VRPX 2016
  • Country
  • QLGN United States
  • VRPX United States
  • Employees
  • QLGN 4
  • VRPX N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • VRPX Medicinal Chemicals and Botanical Products
  • Sector
  • QLGN Health Care
  • VRPX Health Care
  • Exchange
  • QLGN Nasdaq
  • VRPX Nasdaq
  • Market Cap
  • QLGN 2.7M
  • VRPX 3.7M
  • IPO Year
  • QLGN N/A
  • VRPX 2021
  • Fundamental
  • Price
  • QLGN $3.60
  • VRPX $0.62
  • Analyst Decision
  • QLGN
  • VRPX Hold
  • Analyst Count
  • QLGN 0
  • VRPX 1
  • Target Price
  • QLGN N/A
  • VRPX N/A
  • AVG Volume (30 Days)
  • QLGN 226.0K
  • VRPX 108.5K
  • Earning Date
  • QLGN 11-29-2024
  • VRPX 11-26-2024
  • Dividend Yield
  • QLGN N/A
  • VRPX N/A
  • EPS Growth
  • QLGN N/A
  • VRPX N/A
  • EPS
  • QLGN N/A
  • VRPX N/A
  • Revenue
  • QLGN N/A
  • VRPX N/A
  • Revenue This Year
  • QLGN N/A
  • VRPX N/A
  • Revenue Next Year
  • QLGN N/A
  • VRPX N/A
  • P/E Ratio
  • QLGN N/A
  • VRPX N/A
  • Revenue Growth
  • QLGN N/A
  • VRPX N/A
  • 52 Week Low
  • QLGN $3.55
  • VRPX $0.36
  • 52 Week High
  • QLGN $39.15
  • VRPX $7.60
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 25.42
  • VRPX 43.76
  • Support Level
  • QLGN $3.71
  • VRPX $0.55
  • Resistance Level
  • QLGN $4.56
  • VRPX $0.79
  • Average True Range (ATR)
  • QLGN 0.65
  • VRPX 0.07
  • MACD
  • QLGN -0.06
  • VRPX -0.01
  • Stochastic Oscillator
  • QLGN 2.08
  • VRPX 27.96

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

About VRPX Virpax Pharmaceuticals Inc.

Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.

Share on Social Networks: